Journal List > Endocrinol Metab > v.25(2) > 1085820

TOOLS
Kim and Kim: Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients (J Korean Endocr Soc 25:37–45, 2010)
Response

Endocrinol Metab 2010;25(2):159-160.

Published online: 10 June 2010

DOI: https://doi.org/10.3803/EnM.2010.25.2.159

Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients (J Korean Endocr Soc 25:37–45, 2010)

Seul Young Kim, Dohee Kim1

Department of Internal Medicine, Chungnam National University, College of Medicine, Daejeon, Korea

1Department of Internal Medicine, Dankook University, College of Medicine, Cheonan, Korea

Copyright © 2010 Korean Endocrine Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

1. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 91:2112–2118. 2006.
crossref
2. Kim JY, Jee JH, Yoon CH, Chung YJ, Lee BW, Cho GY, Kim SY, Chung JH, Min YK, Lee MS, Lee MK, Kim KW. Efficacy of octreotide LAR in acromegalic patients. J Korean Soc Endocrinol. 20:344–352. 2005.
crossref
3. Yang SJ, Seo YJ, Eun CR, Chung HS, Choi HJ, Kim NH, Kim HS, Park JR, Kim DJ, Yoo HJ, Park SY, Lee YJ, Ryu OH, Kim HY, Lee KW, Seo JA, Kim SG, Choi DS, Baik SH. Therapeutic effects of a long-acting formulation of lanreotide in Korean patients with acromegaly. Korean J Med. 73:50–57. 2007.
4. Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf). 63:168–175. 2005.
crossref
5. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J. SMS995B2401 Study Group. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 66:859–868. 2007.
6. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly Clin Endocrinol (Oxf). 68:473–480. 2008.
7. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 93:2957–2968. 2008.
crossref
TOOLS
Similar articles